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Abstract
Background: Sepsis is a prominent reason for intensive care unit (ICU) admission in patients with HIV. We aimed to
investigate the impact of HIV infection on presentation, outcome and host response in sepsis.
Methods: We performed a prospective observational study in the ICUs of two tertiary hospitals. For the current
analyses, we selected all patients diagnosed with sepsis within 24 hours after admission. Host response biomarkers
were analyzed in a more homogeneous subgroup of admissions involving HIV-positive patients with pneumosepsis,
matched to admissions of HIV-negative patients for age, gender and race. Matching was done by nearest neighbor
matching with R package “MatchIt”.
Results: We analyzed 2251 sepsis admissions including 41 (1.8 %) with HIV infection (32 unique patients). HIV-
positive patients were younger and admission of HIV-positive patients more frequently involved pneumonia (73.2 %
versus 48.8 % of admissions of HIV-negative patients, P = 0.004). Disease severity and mortality up to one year after
admission did not differ according to HIV status. Furthermore, sequential plasma levels of host response biomarkers,
providing insight into activation of the cytokine network, the vascular endothelium and the coagulation system,
were largely similar in matched admissions of HIV-positive and HIV-negative patients with pneumosepsis.
Conclusions: Sepsis is more often caused by pneumonia in HIV-positive patients. HIV infection has little impact on
the disease severity, mortality and host response during sepsis.
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Background
The spectrum of disease in human immunodeficiency
virus (HIV)-infected patients has changed dramatically
since the introduction of combination antiretroviral
therapy (cART) [1]. The incidence of opportunistic
infections has decreased and long-term survival has
improved to an extent that HIV infection has become a
chronic disease [1]. However, invasive bacterial infections
and sepsis remain an important cause of morbidity and
mortality in patients with HIV [2, 3], and previous studies
have demonstrated the importance of sepsis as a reason
for intensive care unit (ICU) admission [3–8]. Advanced
HIV infection has been associated with higher mortality in
patients with sepsis compared to mortality in HIV-
negative patients with sepsis [9–11].
Sepsis is characterized by an imbalanced host
response, characterized amongst other factors by release
of proinflammatory and anti-inflammatory cytokines,
activation of the vascular endothelium and stimulation
of the coagulation system with concurrent impairment
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of anticoagulant mechanisms [12]. HIV infection is asso-
ciated with activation and deregulation of several cellular
and mediator pathways also implicated in the pathogen-
esis of sepsis, which has led to the hypothesis that HIV
infection may further disturb the host response in sepsis
[13]. However, few studies have investigated the immune
response to sepsis in patients with HIV co-infection.
We aimed to compare the presentation and outcome
of sepsis in the presence or absence of HIV co-infection
in an area with widely available cART. In addition, in a
more homogeneous subgroup of patients with pneumo-
sepsis, we sought to obtain insight into the influence of
HIV co-infection on the host response.
Methods
Study design, patients and definitions
This study was conducted as part of the Molecular
Diagnosis and Risk Stratification of Sepsis (MARS)
project, a prospective observational study in the ICUs of
two tertiary teaching hospitals (Academic Medical
Center in Amsterdam and University Medical Center
Utrecht, The Netherlands) [14]. Trained ICU researchers
prospectively collected demographic, clinical, microbio-
logical and interventional data [14]. In the MARS study,
assignment of pathogens to pneumonia cases was based
on post hoc physician assessment, using all available
information, including pathogens cultured from blood,
lower respiratory tract samples and respiratory secre-
tions and serology and PCR results, combined with the
clinical decision to treat the patient for the particular
causative pathogen, in multidisciplinary meetings.
Information on CD4 counts, viral loads and cART was
collected from patient files. CD4 counts and viral loads
measured between 120 days prior to and 30 days after
admission were considered representative. If multiple
samples were available, the first sample was included in
our analyses. Organ failure was defined by a score of 3
or greater on the Sequential Organ Failure Assessment
(SOFA) score, or a score of 1 or more for cardiovascular
failure [15]. Shock was defined by the use of vasopressors
(noradrenaline) for hypotension in a dose of 0.1 mcg/kg/
min during at least 50 % of the ICU day. The plausibility
of infection was assessed post hoc and classified on a 4-
point scale (none, possible, probable or definite) according
to Center for Disease Control and Prevention [16] and
International Sepsis Forum consensus definitions [14, 17].
For the current analysis we selected all patients admit-
ted to the ICU between January 2011 and July 2013 with
sepsis diagnosed within 24 hours after ICU admission,
defined as the presence of infection combined with at
least one additional parameter as described in the 2001
International Sepsis Definitions Conference [18]. Pa-
tients with a post hoc infection likelihood of “none”
were excluded, as were patients transferred from
another ICU, except for those referred to one of the
study centers on the day of admission. The Municipal
Personal Records Database was consulted to determine
survival up to one year after ICU admission. In The
Netherlands, all deaths are immediately reported to this
database, so this provides a reliable and up-to-date
means to assess mortality. If a patient had multiple ad-
missions, only the first admission was used to assess
mortality.
Biomarker measurements
Daily (at admission and at 6 a.m. thereafter) left-over
plasma (obtained from blood drawn for routine patient
monitoring) was stored within 4 hours at -80 °C. All
measurements were done in EDTA anticoagulated plasma
obtained on admission (day 0) and days 2 and 4. Tumor
necrosis factor alpha (TNF-α), interleukin-1beta (IL-1β),
interferon-gamma (IFN-γ), IL-6, IL-8, IL-10, IL-13,
soluble intercellular adhesion molecule-1 (ICAM-1) and
soluble E-selectin were measured using FlexSet cytometric
bead arrays (BD Bioscience, San Jose, CA, USA) using
FACS Calibur (Becton Dickenson, Franklin Lakes, NJ,
USA). Angiopoietin-1, angiopoietin-2, protein C, anti-
thrombin (R&D systems, Abingdon, UK), and D-dimer
(Procartaplex, eBioscience, San Diego, CA, USA) were
measured by Luminex multiplex assay using BioPlex 200
(BioRad, Hercules, CA, USA). Normal biomarker values
were acquired from EDTA plasma from 27 age-matched
and gender-matched healthy volunteers, from whom
written informed consent was obtained.
Statistical analysis
Data-analyses were performed in R (v3.1.1) [19]. Baseline
characteristics of study groups were compared using the
chi-square test for categorical variables and the t test or
Wilcoxon rank sum test for continuous variables. In
order to adjust for differences in clinical characteristics
between groups, each HIV patient with pneumonia was
matched by age, gender and race (white) to three HIV-
negative controls, using nearest neighbor matching with
R package “MatchIt”. Biomarkers were transformed to a
log scale and mixed models were used to analyze repeated




A total of 6994 admissions, involving 5920 unique pa-
tients, were included during the study period, including
58 admissions of HIV-positive patients (0.8 %). We
excluded 325 admissions because the patients had been
transferred from other ICUs. Of the remaining 6669
admissions, 2251 (1889 patients) had a sepsis diagnosis
in the first 24 hours of ICU admission, including 41
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admissions (1.8 %) of 32 unique patients (1.7 %) with
HIV infection (Table 1). The other 17 HIV-positive
admissions (16 unique patients) during this study period
were for non-infectious reasons, predominantly post-
operative surveillance (n = 4), respiratory insufficiency
(n = 3) and pulmonary embolism (n = 2).
Presentation, cause and outcome of sepsis
Sepsis admissions with HIV co-infection involved
younger patients, who were less likely to be Caucasian,
compared to sepsis admissions without HIV infection
(Table 1). The majority of HIV-positive patient admissions
(n = 29, 70.7 %) involved patients who were on cART, but
only 18 (47.4 %) had complete viral suppression (HIV
load <50 copies/ml). There were 6 admissions (14.6 %)
involving patients presenting with newly diagnosed HIV
infection and the majority of HIV admissions presented
with overt immune suppression (CD4 counts <200
cells/mm3 in 56.1 % and <350 cells/mm3 in 73.2 % of
admissions). Pneumonia was the most common infection
in both HIV-positive and HIV-negative admissions, but
pneumonia was more frequent in HIV-positive patient
admissions (n = 30 (73.2 %) versus 1048 (48.8 %) in
admissions involving patients with sepsis who were HIV-
negative, P = 0.004) (Fig. 1). The proportion of patients
admitted with organ failure or shock was similar in HIV-
positive and HIV-negative patients (Table 1). Likewise, the
occurrence of organ failure and shock at any day during
ICU stay was similar between groups. Crude mortality up
to one year after ICU admission did not differ between
HIV-positive and HIV-negative patients with sepsis.
Presentation, cause and outcome of pneumonia
Considering the strong predominance of pneumonia
amongst HIV-positive admissions, we focused our
further analyses on 30 admissions of HIV-positive
Table 1 Baseline characteristics and outcome of all sepsis admissions stratified according to HIV infection status
HIV-positive (n = 41) HIV-negative (n = 2210) P
Demographicsa
Age, years, mean (SD) 49.6 (12) 60.4 (15.5) <0.0001
Gender, male (%) 24 (75) 1154 (6) 0.14
Race, white (%) 18 (56.2) 1652 (89) 0.005
Admissions
Readmission (%) 9 (22.0) 353 (16.0) 0.39
New HIV diagnosis (%) 6 (14.6) – –
Severity of disease in first 24 hours
SOFA score, median (IQR)b 7 (3-10.5) 7 (4–9) 0.38
Organ failure (%) 35 (85.4) 1802 (81.5) 1
Shock (%) 9 (22) 606 (27.4) 0.50
HIV disease severity and treatment
CD4 count, cells/mm3, median (IQR)c 70 (23-346) – –
Viral load, cp/ml, median (IQR)d 105 (48-54916) – –
On cART (%) 29 (70.7) – –
Viral suppression (%) 18 (47.4) – –
Outcome
Length of ICU stay, median days (IQR) 4 (1–11) 4 (2–8) 0.47
Organ failure during admission (%) 37 (90.2) 1915 (86.7) 0.73
Shock during admission (%) 15 (36.6) 750 (33.9) 0.74
30-day mortality (%)a 6 (18.8) 481 (25.9) 0.42
60-day mortality (%)a 11 (34.4) 568 (30.6) 0.72
90-day mortality (%)a 13 (40.6) 629 (33.9) 0.57
1-year mortality (%)a 16 (50) 794 (42.8) 0.35
aDemographic and mortality data are given for the first ICU admission during the study period; readmissions were not included, resulting in analysis of 32 HIV-
positive patients and 1857 HIV-negative patients. From the total of 2251 admissions, 23 were lost to follow up at day 30 (1 %), 32 at day 60 (1.4 %), 37 at day 90
(1.6 %), and 59 at 1 year (2.6 %) after ICU admission. bThe central nervous system score was excluded from the Sequential Organ Failure Assessment (SOFA) score
calculation, because of a large number of sedated patients. cCD4 counts were available for 39 admissions. In 32 patients (82 %) the CD4 count was obtained within
120 days prior to admission, and 7 patients (18 %) had a CD4 count obtained on admission or within 30 days after admission. dViral loads were available for 39
admissions. Viral suppression was defined as a viral load below the detection limit, which was <40 copies/ml or <50 copies/ml, depending on the hospital labora-
tory. cART combination antiretroviral therapy, IQR interquartile range, SD standard deviation
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patients with pneumosepsis (Table 2). Considering the
large demographic differences according to HIV status,
we composed a control cohort of 90 admissions of HIV-
negative patients with pneumonia, matched for age, sex
and race. In the matched cohort demographic character-
istics were similar between groups. The matched cohort
contained more HIV-positive than HIV-negative patients
who were readmitted. In order to explore reasons for
the relatively high readmission rates amongst HIV-
positive patients we compared HIV-positive admissions
with and without readmission (Additional file 1); this
analysis did not provide a clear explanation. Although
the severity of disease was comparable between HIV-
positive and HIV-negative admissions, as reflected by
the SOFA score and the percentage of patients presenting
with organ failure or shock, HIV-positive pneumosepsis
admissions were significantly less likely to require mech-
anical ventilation in the first 24 hours. Causative patho-
gens in patients with pneumosepsis are outlined in
Table 3. The most common pathogens in HIV-positive ad-
missions were Streptococcus pneumoniae, Staphylococcus
aureus and Pneumocystis jirovecii. While S. pneumoniae
and S. aureus were similarly frequent in HIV-negative
patients, P. jirovecii was more common in HIV-positive
patients compared with unmatched HIV-negative pa-
tients with pneumosepsis, but not when compared to
matched HIV-negative patients with pneumosepsis. In
the latter group P. jirovecii pneumonia occurred in pa-
tients on immunosuppressive therapy. Cytomegalovirus
(CMV) was a more frequent pathogen in HIV-positive
admissions, both in unmatched and matched analyses.
Crude mortality up to one year after ICU admission did
not differ between HIV-positive and HIV-negative pa-
tients with pneumonia (either unmatched or matched)
(Table 2).
Host response biomarkers in pneumosepsis
To obtain insight into the influence of HIV infection on
the host response to sepsis we measured 14 biomarkers
indicative of activation and/or deregulation of key
pathways implicated in sepsis pathogenesis in 30 HIV-
positive and 90 matched HIV-negative pneumosepsis
admissions. As expected [20, 21], patients with sepsis
displayed activation of the cytokine network (Fig. 2), the
vascular endothelium (Fig. 3) and the coagulation system
(Fig. 4). The concentrations of most host response bio-
markers were similar in HIV-positive and HIV-negative
admissions, except for IFN-γ and soluble ICAM-1,
which were higher in HIV-positive admissions at days 0
and 2. These differences were no longer statistically
significant when readmissions were excluded, thus ana-
lyzing only the first admission of unique patients (Add-
itional file 2). The plasma concentrations of TNF-α, IL-
1β and IL-13 were undetectable in the majority of
patients and were not different between groups (data
not shown).
Discussion
We studied the impact of HIV infection on the presenta-
tion and outcome of sepsis, and particularly pneumosepsis.
Fig. 1 Primary sites of infection in patients with sepsis admitted to the ICU stratified by HIV status. Numbers in the figure represent the numbers
of patients per group. P values are indicated for differences between HIV-positive and HIV-negative patients at each time point
Wiewel et al. Critical Care  (2016) 20:322 Page 4 of 10
Our main findings were that disease severity and outcome
are remarkably alike in HIV-positive and HIV-negative
patients. In addition, plasma concentrations of biomarkers
indicative of key host responses to sepsis were largely
similar in HIV-positive and HIV-negative patients with
pneumosepsis.
In previous studies, HIV/AIDS was independently
associated with in-hospital mortality in ICU patients
with sepsis [9–11]. These studies differ from the
present investigation in patient selection [9, 10] and
setting [11], which resulted in the inclusion of pa-
tients with more severe disease [9–11]. Standards of
care for HIV patients have improved considerably
over time and previous studies indicate that survival
of critically ill HIV-infected patients continues to im-
prove in the era of widespread availability of cART
[22, 23]. Taken together these data suggest that access
to care (e.g. cART and well-equipped ICUs) is an im-
portant factor in the outcome of sepsis in patients
with HIV.
Table 2 Baseline characteristics and outcome of unmatched and matched admissions for pneumonia stratified by HIV status
Unmatched patients Matched patientsa
HIV-positive (n = 30) HIV-negative (n = 1078) P HIV-negative (n = 90) P
Demographicsb
Age, years, mean (SD) 51.5 (11.1) 60.6 (16.2) 0.001 50.8 (12.9) 0.83
Gender, male (%) 17 (77.3) 604 (64.9) 0.28 69 (84.1) 0.52
Race: white (%) 14 (63.6) 831 (89.3) 0.002 67 (81.7) 0.10
Comorbiditiesb
Chronic renal insufficiency (%) 2 (9.1) 101 (10.8) 1 11 (13.4) 0.75
COPD (%) 4 (18.2) 178 (19.1) 1 11 (13.4) 0.73
Diabetes mellitus (%) 3 (13.6) 173 (18.6) 0.59 14 (17.1) 0.76
Hematologic malignancy (%) 5 (22.7) 73 (7.8) 0.03 10 (12.2) 0.30
Hypertension (%) 8 (36.4) 277 (29.8) 0.63 14 (17.1) 0.08
Liver cirrhosis (%) 1 (4.5) 16 (1.7) 0.32 2 (2.4) 1
Metastatic malignancy (%) 2 (9.1) 28 (3) 0.16 2 (2.4) 0.20
Non-metastatic malignancy (%) 2 (9.1) 96 (10.3) 1 5 (6.1) 0.64
Admissions
Readmission (%) 8 (26.7) 147 (13.6) 0.06 8 (8.9) 0.03
Community-acquired pneumonia (%) 18 (60) 565 (52.4) 0.44 56 (62.2) 1
Severity of disease in first 24 hours
SOFA score, median (IQR) 6 (4–8) 7 (3–10) 0.30 7 (4-9) 0.89
Organ failure (%) 884 (82) 25 (83.3) 1 81 (90) 0.70
Shock (%) 262 (24.3) 8 (26.7) 0.84 35 (38.9) 0.53
Supportive care in the first 24 hours
Mechanical ventilation (%) 20 (66.7) 859 (79.7) 0.12 81 (90) 0.006
Renal replacement therapy (%) 2 (6.7) 69 (6.4) 1 8 (8.9) 1
Outcome
Length of stay ICU, median days (IQR) 5 (1-15) 4 (2-9) 0.70 6 (3-11) 0.33
Organ failure during admission (%) 27 (90) 951 (88.2) 1 87 (96.7) 0.26
Shock during admission (%) 14 (46.7) 340 (31.5) 0.10 35 (38.9) 0.53
30-day mortality (%)b 4 (18.2) 244 (26.2) 0.47 19 (23.2) 0.79
60-day mortality (%)b 8 (36.4) 290 (31.1) 0.67 22 (26.8) 0.43
90-day mortality (%)b 9 (40.9) 319 (34.3) 0.66 22 (26.8) 0.30
1-year mortality (%)b 11 (50) 412 (44.3) 0.66 25 (30.5) 0.12
Results are presented as number (%) unless stated otherwise. aPatients were matched for age, gender and race and compared with HIV-positive patients.
bDemographics and mortality data are given for the first ICU admission during the study period; readmissions were not included, resulting in analysis from 22
HIV-positive patients, 931 HIV-negative unmatched and 82 HIV-negative matched patients. cART combination antiretroviral therapy, COPD chronic obstructive
pulmonary disease, ICU intensive care unit, IQR interquartile range, SD standard deviation, SOFA Sequential Organ Failure Assessment
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Pneumonia was a more frequent presentation in pa-
tients with sepsis and HIV co-infection. Previously, pneu-
monia was shown to be a major source of morbidity in
HIV, even in patients with high CD4 cell counts [24]. Prior
to the wide availability of cART, P jirovecii pneumonia
was a common reason for ICU admission [25, 26]. In our
cohort P. jirovecii was a more common pathogen in HIV-
positive patients, in addition to CMV, but the numbers of
these opportunistic pathogens were relatively small, with
the majority of pneumonia cases being caused by bacterial
pathogens, similar to HIV-negative patients. However, in-
terpretation of these findings is limited by the fact that
we were unable to identify a causative pathogen in ap-
proximately half of our patients and that the causative
role of CMV ideally is confirmed by tissue examination,
which was not routinely done. Although our data do
not show differences in disease severity, mechanical
ventilation in the first 24 hours after ICU admission
was applied less frequently in HIV-positive patients
with pneumonia.
We sought to examine the effect of HIV infection on
the host response in a matched subgroup of patients
with pneumosepsis. Previous reports on the host
response to sepsis in adult patients with HIV are limited
to two investigations from Brazil in which plasma
cytokine levels were studied [27, 28]. Few differences
according to HIV status were observed, but one of
these studies reported higher plasma IL-10 in the
presence of unaltered IL-6 among HIV-positive pa-
tients with sepsis [28]. Notably, these encompassed
only patients with advanced AIDS-defining disease,
HIV-negative control groups unmatched for age and
site of infection, and very high mortality rates (around
50 %) [27, 28].
We analyzed host response biomarkers in a relatively
homogeneous cohort of patients with pneumosepsis
matched for age, gender and white race, and found no
differences in the plasma levels of proinflammatory and
anti-inflammatory cytokines, with the sole exception of
IFN-γ. The main producers of IFN-γ are activated
Table 3 Causative pathogens in all unmatched and matched patients with pneumonia stratified according to HIV status
Unmatched patients Matched patients
HIV-positive (n = 30) HIV-negative (n = 1078) P HIV-negative (n = 90) P
Gram-positive bacteria (%) 8 (26.7) 216 (20) 0.52 18 (20.0) 0.44
Streptococcus pneumoniae (%) 4 (13.3) 71 (6.6) 0.27 5 (5.6) 0.22
Streptococcus species (%) 0 19 (1.8) 0.67 3 (3.3) 0.56
Staphylococcus aureus (%) 4 (13.3) 99 (9.2) 0.52 6 (6.7) 0.27
Other Gram-positive bacteria (%) 0 27 (2.5) 0.62 4 (4.4) 0.58
Gram-negative bacteria (%) 3 (10.0) 349 (32.4) 0.0075 36 (40.0) 0.011
Haemophilus influenzae (%) 0 70 (6.5) 0.26 9 (10) 0.11
Escherichia coli (%) 1 (3.3) 65 (6) 0.71 5 (5.6) 1
Pseudomonas aeruginosa (%) 0 64 (5.9) 0.25 6 (6.7) 0.33
Klebsiella pneumoniae (%) 1 (3.3) 29 (2.7) 1 3 (3.3) 1
Enterobacter cloacae (%) 0 25 (2.3) 0.63 1 (1.1) 1
Stenotrophomonas maltophilia (%) 1 (3.3) 11 (1) 0.28 1 (1.1) 0.44
Other Gram-negative bacteria (%) 0 85 (7.9) 0.18 11 (12.2) 0.06
Yeast/fungi (%) 6 (20.0) 84 (7.8) 0.036 18 (20.0) 1
Aspergillus species (%) 1 (3.3) 40 (3.7) 1 9 (10) 0.44
Pneumocystis jirovecii (%) 4 (13.3) 15 (1.4) 0.004 5 (5.6) 0.22
Other yeasts or fungi (%) 1 (3.3) 29 (2.7) 1 4 (4.4) 1
Viruses (%) 3 (10.0) 70 (6.5) 0.72 10 (11.1) 1
Influenza (%) 0 38 (3.5) 0.41 8 (8.9) 0.19
Cytomegalovirus (%) 2 (6.7) 5 (0.5) 0.019 0 0.049
Other viruses (%) 1 (3.3) 27 (2.5) 1 2 (2.2) 1
Atypical mycobacteria (%) 1 (3.3) a 1 (0.1) b 0.053 0 0.24
Unknown (%) 15 (50) 500 (46.4) 1 30 (33.3) 0.10
Results are presented as number (%). Percentages represent the proportion of pneumonia cases caused by the particular pathogen. Multiple causative pathogens
were isolated in some patients with pneumonia. aMycobacterium avium. bMycobacterium xenopi
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natural killer (NK) cells, T-helper-1 cells, and cytotoxic
T cells [29]. Our finding of higher plasma IFN-ɣ in
patients with sepsis and HIV co-infection, which was
sustained up to two days after ICU admission, is remark-
able, as patients with HIV generally have reduced num-
bers of circulating NK cells and T-helper-1 cells [13].
Furthermore, NK cells from untreated HIV patients re-
leased less IFN-γ in response to bacterial stimulation
than NK cells from HIV-negative controls [30]. The
clinical and biological relevance of (modestly) elevated
IFN-γ levels in HIV-infected patients with sepsis remains
to be established.
Chronic HIV infection is associated with endothelial
cell activation and damage [13], responses that are
almost invariably also found in patients with sepsis [31].
In Malawian children with severe bacterial infection, a
Fig. 2 Cytokine levels in matched patients with pneumonia stratified according to HIV infection status. Plasma cytokine levels on days 0, 2 and 4
after intensive care unit admission. Data in box-and-whisker diagrams depict the median and lower quartile, upper quartile and respective 1.5 IQR
as whiskers (as specified by Tukey). Dashed lines represent median in 27 healthy volunteers. P values are indicated for differences between HIV-positive
and HIV negative-patients at each time point. IFN interferon, IL interleukin
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greater increase in plasma angiopoietin-2, an angiogenic
peptide that increases endothelial activation and vascular
permeability, was observed in patients with HIV co-
infection [32]. In our adult ICU patients with pneumo-
sepsis, plasma levels of specific endothelial cell activation
markers (angiopoietin-1 and -2, and soluble E-selectin)
did not differ according to HIV status. We did observe
higher levels of soluble ICAM-1 in HIV-positive patients
with pneumosepsis, which can be shed by both endothe-
lial cells and leukocytes. HIV infection can stimulate the
release of exosomes containing ADAM metallopeptidase
domain 17 (ADAM17), the cleaving protease for ICAM-
1, which promotes ICAM-1 shedding [33]. Increased
levels of IFN-ɣ, as observed in our study, may also con-
tribute to the release of soluble ICAM-1 [34]. Although
previous studies have described a procoagulant state in
patients with HIV [35, 36], plasma levels of D-dimer,
protein C and antithrombin were similar in HIV-positive
and HIV-negative patients with pneumosepsis. These re-
sults indicate that HIV infection has no additive effect
on activation of the vascular endothelium and coagula-
tion in critically ill patients with pneumonia.
Our study has strengths and limitations. We prospect-
ively analyzed all consecutive patients admitted with sepsis
to two ICUs during a 2.5-year period. Nonetheless, the
number of HIV-positive patients with sepsis was limited,
precluding stratification according to HIV disease pro-
gression. HIV testing is not standard for all ICU patients;
thus, our control group may have contained cases with
unrecognized HIV infection. However, The Netherlands
Fig. 3 Endothelial cell activation markers in matched patients with pneumonia stratified according to HIV infection status. Plasma levels of soluble
E-selectin, soluble intercellular adhesion molecule-1 (ICAM-1), angiopoietin-1 and angiopoietin-2 on days 0, 2 and 4 after intensive care unit admission.
Data in box-and-whisker diagrams depict the median and lower quartile, upper quartile and the respective 1.5 IQR as whiskers (as specified by Tukey).
Dashed lines represent median levels in 27 healthy volunteers. P values are indicated for differences between HIV-positive and HIV-negative patients at
each time point
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has a low HIV prevalence of around 0.2 %, so this is
unlikely to influence our results [37]. This study was con-
ducted in two academic ICUs and therefore generalization
of results should be done with caution. Sepsis was defined
using the 2001 consensus definition [18]; the vast majority
of included patients had a SOFA score ≥2 at ICU admis-
sion, which approximates the recently updated consensus
definitions for sepsis [38]. Finally, known HIV infection
may lead to selection bias in admittance to ICU and/or
the extent of aggressive therapy.
Conclusions
Pneumonia is the main cause of sepsis in HIV-positive
ICU patients, and is more frequent compared to patients
without HIV infection. Otherwise, our results indicate that
in a high-resource setting with excellent access to care
and HIV treatment, HIV infection has little, if any, influ-
ence on the clinical and pathophysiological course of sep-
sis requiring ICU admission. These findings support the
notion that the presence of HIV co-infection should not
play a major role in the decision whether or not to admit
critically ill patients with sepsis to the ICU.
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